Author(s):
Aria Salari, Hasan Rezazadeh, Hasti Hoseini
Email(s):
hosseini.2000@gmail.com
DOI:
10.52711/0974-360X.2024.00860 
Address:
Aria Salari1, Hasan Rezazadeh2, Hasti Hoseini3*
1Student, Faculty of Dentistry, Kerman University of Medical Sciences, Kerman, Iran.
2Student, Student Research Committee, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
3Student, Student Research Committee, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
*Corresponding Author
Published In:
Volume - 17,
Issue - 11,
Year - 2024
ABSTRACT:
In individuals with covid-19, oral candidiasis is apparent, particularly in severe cases, presenting various symptoms such as white lesions on the tongue and oral mucosa. A majority of covid-19 patients who develop oral candidiasis are typically above 50 years of age (Mean age: 53.24 years), often with preexisting conditions like cardiovascular diseases and cancer. The treatment approach for oral candidiasis in covid-19 patients commonly includes the administration of corticosteroids, broad-spectrum antibiotics, and various other pharmaceuticals. The incidence of oral/oropharyngeal candidiasis is higher in men (Mean: 39.8; CI: 10.32-69.28) compared to women (Mean: 31; CI: 9.72-52.38). The initiation of oral candidiasis displays variability among individuals, with symptoms becoming apparent between 1 to 30 days after the onset of covid-19 symptoms. Frequently utilized medications comprise antivirals, antibiotics, anthelmintics, corticosteroids, acetylsalicylic acid, and indomethacin. The use of broad-spectrum antibiotics has been associated with an increased susceptibility to oral candidiasis. Corticosteroids have the potential to disrupt the oral microbiome, thereby fostering the development of oral candidiasis. In the early phases of the pandemic, medications like azithromycin, respiratory fluoroquinolones, cephalosporins, and linezolid were at times prescribed. The onset of oral candidiasis in covid-19 patients can vary, occurring between 1 to 30 days after the onset of covid-19 symptoms. In conclusion, the immune dysfunctions induced by covid-19 significantly impede the body's ability to combat fungal pathogens such as Candidia albicans, particularly due to inadequate hygiene practices. Understanding the dysregulation of key immune pathways, including Toll-like receptors and the NLRP3 inflammasome, is imperative in elucidating their roles in covid-19 and subsequent fungal infections.
Cite this article:
Aria Salari, Hasan Rezazadeh, Hasti Hoseini. Examination of Oropharyngeal candidiasis in Infectious patients caused by the Corona Virus Epidemic: A Review Article. Research Journal of Pharmacy and Technology. 2024; 17(11):5646-2. doi: 10.52711/0974-360X.2024.00860
Cite(Electronic):
Aria Salari, Hasan Rezazadeh, Hasti Hoseini. Examination of Oropharyngeal candidiasis in Infectious patients caused by the Corona Virus Epidemic: A Review Article. Research Journal of Pharmacy and Technology. 2024; 17(11):5646-2. doi: 10.52711/0974-360X.2024.00860 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-11-68
REFERENCES:
1. Muliana H, Suprapti B. The Satisfaction of Covid-19 patients Self-home Care with Telepharmacy Services. Research Journal of Pharmacy and Technology. 2022; 15(12): 5583-8. DOI: 10.52711/0974-360X.2022.00943
2. Debnath S, Saha J. Coronavirus disease (COVID-19): A global threat. Asian Journal of Pharmcy and Technology. 2022; 12(1): 63–9. DOI: 10.52711/2231-5713.2022.00011
3. Sills E S, Wood S H. An Experimental Model for Peri-conceptual COVID-19 Pregnancy Loss and Proposed Interventions to Optimize Outcomes. International Journal of Molecular and Cellular Medicine. 2020; 9 (3): 180-187. doi: 10.22088/IJMCM.BUMS.9.3.180
4. Najafipour R, Mohammadi D, Momeni M, Moghbelinejad S. ACE-2 Expression and Methylation Pattern in Bronchoalveolar Lavage Fluid and Bloods of Iranian ARDS Covid-19 Patients. International Journal of Molecular and Cellular Medicine. 2022; 11 (1):55-63. doi: 10.22088/IJMCM.BUMS.11.1.55
5. Dameh M, Ameen Baqer A, Zaidi M, K. Hachim S, M. Hameed N, A. Awadh S, Obaid AJ, Adhab Z. H. Evaluating the efficacy of flavonoids from Capparis spinosa extracts in treatment of Candida vulvovaginitis. Caspian Journal of Environmental Sciences, 2022; 20(3): 565-570. doi: 10.22124/cjes.2022.5692
6. Najafipour R, Mohammadi D, Momeni M, Moghbelinejad S. ACE-2 Expression and Methylation Pattern in Bronchoalveolar Lavage Fluid and Bloods of Iranian ARDS Covid-19 Patients. International Journal of Molecular and Cellular Medicine. 2022; 11(1): 55-63. doi: 10.22088/IJMCM.BUMS.11.1.55
7. Widoyo H, Mohammed ZY, Ramírez-Coronel AA, Iswanto AH, Thattarauthodiyil U, Alkhayyat A S, Karimi M, Bahmani M, Eftekhari Z. Herbal therapy in Covid-19: A systematic review of medicinal plants effective against Covid-19. Caspian Journal of Environmental Sciences. 2023; 21(5): 1289-1298. doi: 10.22124/cjes.2023.7431
8. Pankaj Kumar. Corona (COVID-19) period contemplation: Our Environment during SARS CoV-2. Journal of Chemical Health Risks 2024; 14(2): 3187-3198.
9. Jaha HF, Anwar Y, Almaaqar S, Khan T, Khan SB. Iron-Based Nanoparticles Synthesis, Characterization, and Antimicrobial Effectiveness. Advancements in Life Sciences. 2024; 11(2): 525-32.
10. Abbasi, N., Akhavan, M. M., Rahbar‐Roshandel, N., & Shafiei, M. The effects of low and high concentrations of luteolin on cultured human endothelial cells under normal and glucotoxic conditions: involvement of integrin‐linked kinase and cyclooxygenase‐2. Phytotherapy Research 2014; 28(9): 1301-1307.
11. Karimi M, Gholami-Ahangaran M. A Brief Report on Current Evidence of Traditional Chinese Medicine in the Treatment of Patients Infected with SARS-CoV-2. Plant Biotechnol Persa. 2021; 3(1): 34-36. doi: 10.52547/pbp.3.1.1
12. Mussavi M, Asadollahi K, Janbaz F, Mansoori E, Abbasi N. The evaluation of red reflex sensitivity and specificity test among neonates in different conditions. Iranian Journal of Pediatrics 2014; 24(6): 697.
13. Pirhadi M. Investigating the role of medicinal plants in reducing stress caused by COVID-19. Journal of Biochemicals and Phytomedicine. 2023; 2(2): 91–93. doi: 10.34172/jbp.2023.19.
14. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen M, et al. Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19. Allergy. 2020;75(7):1564–81.doi: 10.1111/all.14364.
15. Agnihotri J, Yadav P, Maurya A, Vishwakarma A. Novel chewable gum sticks for the treatment of oral candidiasis. Research Journal of Pharmacy and Technology. 2023; 16(8): 3843–6. doi: 10.52711/0974-360X.2023.00634
16. Moser D, Biere K, Han B, Hoerl M, Schelling G, Chouker A, et al. COVID-19 impairs immune response to Candida albicans. Front Immunology. 2021; 12: 640-644. doi: 10.3389/fimmu.2021.640644.
17. Kox M, Frenzel T, Schouten J, van de Veerdonk FL, Koenen HJPM, Pickkers P. COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients. Critical Care. 2020; 24: 1–4. doi: 10.1186/s13054-020-02896-5.
18. Pence BD. Severe COVID-19 and aging: are monocytes the key? Geroscience. 2020; 42(4): 1051–61. doi: 10.1007/s11357-020-00213-0
19. Nobile CJ, Johnson AD. Candida albicans Biofilms and Human Disease. Annu Rev Microbiology. 2015; 69: 71–92. doi: 10.1146/annurev-micro-091014-104330.
20. Turner SA, Butler G. The Candida pathogenic species complex. Cold Spring Harb Perspect Medicine. 2014; 4(9): 019778. doi: 10.1101/cshperspect.a019778
21. Vila T, Sultan AS, Montelongo-Jauregui D, Jabra-Rizk MA. Oral candidiasis: A disease of opportunity. Journal of Fungi. 2020; 6(1): 15.
22. Singh A, Verma R, Murari A, Agrawal A. Oral candidiasis: An overview. Journal of Oral Maxillofac Pathology. 2014;18(1):81-5.
23. Williams M. Modulation of Candida albicans-associated denture biofilms by environmental and microbial factors. Cardiff University; 2023; 4(2): 1.
24. Budtz-Jørgensen E. Ecology of Candida-associated denture stomatitis. Microb Ecology Health Disease. 2000; 12(3): 170–85.
25. Ghannoum M, Radwan S. Candida Adherence to Epithelial Cells. Candida Adherence to Epithelial Cells. 2018; 1–270. https://doi.org/10.1201/9781351070416
26. Ramakrishna A, Nandini DB, Annigeri R. Candidiasis-A frequently underdiagnosed entity. CODS-Journal Dentistry. 2016; 6(2): 117–21. doi:10.5005/cods-6-2-117
27. Murtiastutik D, Hidayati AN, Widyantari S, Saputri BYA, Bintanjoyo L, Ervianti E, et al. Evaluation of the Antifungal effects of Rosemary Oil and comparison with Nystatin on the Growth of Candida species isolates from HIV/AIDS patients with Oral Candidiasis. Research Journal of Pharmacy and Technology. 2022; 15(8): 3755–8.
28. Al-Hatmi AMS, Mohsin J, Al-Huraizi A, Khamis F. COVID-19 associated invasive candidiasis. Journal of Infectious. 2021; 82(2): 45–6. doi: 10.1016/j.jinf.2020.08.005
29. Kandula UR, Veerabhadrappa KV, Goruntla N, Woldemichael B, Kediro A, Madhale MD, et al. Knowledge, concept on severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). A review of the literature and future perspective. Research Journal of Pharmacy and Technology. 2023; 16(1): 441–6.
30. Oves M, Rauf MA, Husain FM, Zubair M, Ismail IMI, Iyer A. Fungal Infection: The Hidden Enemy? Diabet Foot Ulcer An Updat. 2021;161–76.
31. Richardson MD. Opportunistic and pathogenic fungi. Journal of Antimicrob Chemotherapy. 1991; 28(suppl_A):1–11.
32. Salehi M, Ahmadikia K, Mahmoudi S, Kalantari S, Jamalimoghadamsiahkali S, Izadi A, et al. Oropharyngeal candidiasis in hospitalised COVID‐19 patients from Iran: Species identification and antifungal susceptibility pattern. Mycoses. 2020; 63(8): 771–8. doi: 10.1111/myc.13137.
33. Di Spirito F, Iandolo A, Amato A, Caggiano M, Raimondo A, Lembo S, et al. Prevalence, features and degree of association of oral lesions in COVID-19: a systematic review of systematic reviews. Int J Environ Res Public Health. 2022; 19(12): 7486. doi: 10.3390/ijerph19127486
34. Murtiastutik D, Listiawan MY, Bintanjoyo L, Hidayati AN, Widyantari S, Sari M. Ketoconazole: A Re-emerging choice for Oral candidiasis in patients with human immunodeficiency virus infection/acquired Immunodeficiency Syndrome. Research Journal of Pharmacy and Technology. 2022; 15(3): 1071–6.
35. Mhaske NS, Bura AR, Chavan AN, Bargal DS, Hemanani JM, Allat SA. The Management and Present Treatment on Oropharyngeal Cancer. Asian Journal of Research Pharm Sciences. 2018; 8(2): 91–9. doi: 10.12688/f1000research.14416.1
36. Babamahmoodi F, Rezai MS, Ahangarkani F, Mohammadi Kali A, Alizadeh-Navaei R, Alishahi A, et al. Multiple Candida strains causing oral infection in COVID-19 patients under corticosteroids and antibiotic therapy: An observational study. Front Cell Infectious Microbiology. 2022; 12: 1103226. doi: 10.3389/fcimb.2022.1103226
37. Zahornacky O, Porubčin Š, Rovnakova A, Jarcuska P. Multisystem inflammatory syndrome in adults Associated with recent infection with COVID-19. Diagnostics. 2023; 13(5): 983. doi: 10.3390/diagnostics13050983.
38. Calder PC. Nutrition, immunity and COVID-19. BMJ Nutr Prev Heal. 2020; 3(1): 74.
39. Wagle MM, Lobo KN, Kanchan RR, Chandrashekar A, Subrahmanyam VM. A combination approach using areca nut and ketoconazole for treating cutaneous candidiasis. Research Journal of Pharmacy and Technology. 2021; 14(6): 3074–6.
40. Janjua OS, Shaikh MS, Fareed MA, Qureshi SM, Khan MI, Hashem D, et al. Dental and oral manifestations of COVID-19 related mucormycosis: diagnoses, management strategies and outcomes. Journal of Fungi. 2021; 8(1): 44. doi: 10.3390/jof8010044
41. Naqvi AR, Schwartz J, Brandini DA, Schaller S, Hussein H, Valverde A, et al. COVID-19 and oral diseases: Assessing manifestations of a new pathogen in oral infections. Int Rev Immunology. 2022; 41(4): 423–37. doi: 10.1080/08830185.2021.1967949.
42. Riad A, Gomaa E, Hockova B, Klugar M. Oral candidiasis of COVID‐19 patients: Case report and review of evidence. Journal of Cosmetic Dermatology. 2021; 20(6): 1580. doi: 10.1111/jocd.14066.
43. Rizak G, Maltsev D, Karkimbayeva G, Vivsyannuk V, Barabanchyk O. European and National measurements of Molecular and Immunological aspects of Diagnosis, Prevention, and Treatment of Coronavirus infection. Research Journal of Pharmacy and Technology. 2023;16(8): 3929–35. doi: 10.52711/0974-360X.2023.00646
44. Baraboutis IG, Gargalianos P, Aggelonidou E, Adraktas A. Initial real-life experience from a designated COVID-19 centre in Athens, Greece: a proposed therapeutic algorithm. SN Compr Clinical Medicine. 2020; 2(6): 689–93.
45. Nambiar M, Varma SR, Jaber M, Sreelatha S V, Thomas B, Nair AS. Mycotic infections–mucormycosis and oral candidiasis associated with Covid-19: a significant and challenging association. Journal of Oral Microbiology. 2021; 13(1): 1967699. doi: 10.1080/20002297.2021.1967699
46. Jeronimo LS, Esteves Lima RP, Suzuki TYU, Discacciati JAC, Bhering CLB. Oral candidiasis and covid-19 in users of removable dentures: is special oral care needed? Gerontology. 2022; 68(1): 80–5. doi: 10.1159/000515214.
47. Pereira R, Dos Santos Fontenelle RO, De Brito EHS, De Morais SM. Biofilm of Candida albicans: formation, regulation and resistance. Journal of Applied Microbiology. 2021; 131(1): 11–22.
48. Tsui C, Kong EF, Jabra-Rizk MA. Pathogenesis of Candida albicans biofilm. FEMS Pathogenesis Disease. 2016;74(4): 18.
49. Atriwal T, Azeem K, Husain FM, Hussain A, Khan MN, Alajmi MF, et al. Mechanistic understanding of Candida albicans biofilm formation and approaches for its inhibition. Front Microbiology. 2021; 12: 638609. https://doi.org/10.3389/fmicb.2021.638609
50. Rudrapal M, Khairnar SJ, Borse LB, Jadhav AG. Coronavirus disease-2019 (COVID-19): an updated review. Drug Res (Stuttg). 2020; 70(9): 389–400.
51. Knight L, Fletcher J. Growth of Candida albicans in saliva: stimulation by glucose associated with antibiotics, corticosteroids, and diabetes mellitus. Journal of Infectious Disease. 1971; 371–7.
52. Dogan M, Şahiner U, Ataç A, Ballikaya E, Uysal Soyer Ö, Şekerel B. Oral health status of asthmatic children using inhaled corticosteroids. Turk Journal of Pediatrcs. 2021; 63(1). doi: 10.24953/turkjped.2021.01.009.
53. Kuna P. Longterm effects of steroid therapy. Wiad Lek (Warsaw, Pol 1960). 1998;51:12–8.
54. Vincent JL, Anaissie E, Bruining H, Demajo W, El-Ebiary M, Haber J, et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Medicine. 1998; 24: 206–16.doi: 10.1007/s001340050552.
55. Akhtar Z, Mah-E-Muneer S, Rashid MM, Ahmed MS, Islam MA, Chowdhury S, et al. Antibiotics use and its knowledge in the community: a mobile phone survey during the COVID-19 pandemic in Bangladesh. Antibiotics. 2021; 10(9): 1052. https://doi.org/10.3390/antibiotics10091052
56. Sieswerda E, de Boer MGJ, Bonten MMJ, Boersma WG, Jonkers RE, Aleva RM, et al. Recommendations for antibacterial therapy in adults with COVID-19 - an evidence based guideline. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Disease. 2021; 27(1): 61–6. doi: 10.1016/j.cmi.2020.09.041.
57. Favia G, Tempesta A, Barile G, Brienza N, Capodiferro S, Vestito MC, et al. COVID-19 symptomatic patients with oral lesions: clinical and histopathological study on 123 cases of the University Hospital Policlinic of Bari with a purpose of a new classification. Journal of Clinical Medicine. 2021; 10(4): 757. doi: 10.3390/jcm10040757.
58. Corchuelo J, Ulloa FC. Oral manifestations in a patient with a history of asymptomatic COVID-19: Case report. Vol. 100, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Canada. 2020: 154–7. doi: 10.1016/j.ijid.2020.08.071.